Pharmaceutical company Sai Parenteral is opening its IPO today, aiming to raise over Rs 408 crore.
If you’re planning to invest, here’s a simple and clear breakdown of all the key details you should know.
IPO size and price details
The total issue size is around Rs 408 crore.
Rs 285 crore will come from fresh shares issued by the company
Rs 123 crore will come from promoters selling their stake (OFS)
The price band for the IPO is set between Rs 372 and Rs 392 per share.
In the grey market, the stock is currently trading flat, which suggests a possible listing around the same price of Rs 392.
This means there is no strong early signal of listing gains.
Important dates to keep in mind
The IPO will be open for bidding from March 24 to March 27.
Here’s what happens next:
Allotment is expected by March 30
Shares may be credited to demat accounts by April 1
Listing is likely on April 2
Make sure you apply within the timeline if you’re interested.
How much investment is required?
For retail investors, the minimum investment is quite straightforward:
1 lot = 38 shares
Investment amount = Rs 14,896 (at upper price)
For other categories:
Small NIIs: Around Rs 2.08 lakh
Big NIIs: Around Rs 10.12 lakh
This makes it accessible for retail investors while also allowing larger participation.
What does GMP indicate right now?
The Grey Market Premium (GMP) for this IPO is currently zero.
This suggests that the market is not expecting strong listing gains at the moment.
However, GMP is not an official indicator and can change based on demand and overall market conditions.
How will the company use the money?
The company plans to use the funds mainly for business growth and stability.
Key uses include:
Expanding production capacity
Setting up new R&D centres
Meeting working capital needs
Repaying existing loans
General corporate purposes
This shows that the company is focusing on both expansion and improving its financial position.
Final takeaway
Sai Parenteral’s IPO offers a mix of steady business plans but muted market excitement so far.
If you are looking for long-term potential, it may be worth analysing further.
But if your goal is quick listing gains, the current signals appear limited.
